Italia markets closed

CEL-SCI Corporation (CVM)

NYSE American - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,2700+0,3500 (+11,99%)
Alla chiusura: 04:00PM EDT
3,3000 +0,03 (+0,92%)
Dopo ore: 05:05PM EDT
Accedi per pubblicare un messaggio.
  • J
    Jill
    $NWBO conversation
    Who’s better at burying failed phase 3 trials - Linda Powers or $CVM CEO Geert Kersten?
  • C
    CoolQ
    CEL-SCI Corporation
    Good Luck to #ATNF today their article was posted in the Lancet. You could not doubt their drug once you read about their science team.
    #CVM will be in a journal in June, just in time to use the data for the conference.
    cheers!
  • D
    David
    $CVM conversation
    posted on another forum

    brrrrito
    Bullish
    12:35 AM
    $CVM
    ASCO abstracts will be published in a supplement to Journal of Clinical Oncology. It's a (the) peer reviewed journal. Would make sense to have the papers published in JCO as well? They put out issues quite often: https://ascopubs.org/loi/jco
  • D
    David
    $CVM conversation
    from another forum

    NavyPatrol657
    Bullish
    5/1/22, 10:59 AM
    $CVM

    Just did a really quick comparison look at the two main presentation sessions at ASCO for the Head and Neck Cancer "Track." 15 oral abstracts and 91 poster sessions to be presented for that track.

    While approximately 10 presenters of these 106 total abstracts reference P3 or PIII in their abstract title. Only ONE mentions "Overall Survival" let alone adds the word "EXTENDS." I'm guessing you know who that is!
  • C
    CoolQ
    $NWBO conversation
    I barely got in here at $1.40. I've been waiting for $CVM which is presenting at ASCO in June. I think both of these have a chance at good returns in a bad market. The drugs work! Cheers!
  • D
    David
    $CVM conversation
    Adam Feuerstein
    @adamfeuerstein
    ·
    Apr 22
    One year later, we may finally learn how badly $CVM Multikine failed its Ph3 study!
  • D
    David
    $CVM conversation
    Like Geert said ...

    " I'll bet my 4 million shares and options against a short seller any day ! "

    Geert Kersten
    @GeertKersten1
    ·
    Feb 9, 2021
    I just read about a short seller called Aristides Capital who got really hurt shorting $CVM. He actually believes that we have the Phase 3 cancer study data and are not releasing it. Absurd! I am betting my 4 million shares and options against him any day.
  • G
    Guy
    Geert just Tweeted right now On Twitter!
    “ $CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.”
  • D
    David
    $CVM conversation
    Geert Kersten
    @GeertKersten1
    ·
    May 17, 2021
    $CVM To those who think they know what a final data analysis looks like, please read this from FDA. We have hired experts to do this as FDA and our protocol require. We are blinded until the end. I have 4 m shares/warrants at stake and I will wait.

    https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products
  • D
    David
    $CVM conversation
    Like Geeert said ...

    " I have 4 m shares/warrants at stake and I will wait. "

    Geert Kersten
    @GeertKersten1
    ·
    May 17, 2021
    $CVM To those who think they know what a final data analysis looks like, please read this from FDA. We have hired experts to do this as FDA and our protocol require. We are blinded until the end. I have 4 m shares/warrants at stake and I will wait.
  • D
    David
    $CVM conversation
    The rest is background noise.

    Geert Kersten
    @GeertKersten1
    $CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.
  • D
    David
    $CVM conversation
    ALERT Geert Tweet Now

    Geert Kersten
    @GeertKersten1
    $CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.
  • J
    Joe
    $CVM conversation
    From Stocktwits : ttaberhomes
    9m
    $CVM
    We know all the facts, Trial proved very significant 14.1% OS for the predestinated non chemo patient arm. MK is non toxic. So risk reward for patients is excellent and something the FDA will accept. There has not been any new treatment for H&N cancer in a half a century. MK is a great new treatment for this terrible disease. Something that can give hope and increased survival for approximately 210,000 patients world wide annually. I know the shorts and bashers would love for MK not to get approval so they could make a few bucks and brag how the screwed the longs. Very sad. That they could attack a small bio that has worked tirelessly for numerous years to bring a life saving non toxic treatment. So patients can spend more time on this earth with their wives, kids friends and family. They should be ashamed of their selves.
  • D
    David
    $CVM conversation
    Geert Kersten
    @GeertKersten1
    ·
    Jul 2, 2021
    $CVM We showed survival data exceeding all primary endpoints for 1 of 2 treatment arms with no safety issues. On the call yesterday we showed that this analysis was pre-specified in the protocol and conducted BEFORE unblinding, confirmed by the biostatistician, per the FDA rules
  • D
    David
    $CVM conversation
    STOP and THINK about the significance of this statement

    GeertKersten1
    $CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.
  • D
    David
    $CVM conversation
    Geert Kersten
    @GeertKersten1
    ·
    Feb 1, 2021
    $CVM We are beating the shorts. Let’s bring the sole focus back to our Phase 3 cancer study with Multikine. I have complete confidence in Dr. Talor who developed Multikine and has always been right on scientific matter. His team is incredible. If Dr. Talor believes, I believe!
  • D
    David
    $CVM conversation
    Like Geert said ...

    " A landmark cancer study with clinical benefit in an unmet need cannot be held down. "

    Geert Kersten
    @GeertKersten1
    ·
    May 17, 2021
    $CVM ‘s work is checked regularly by regulators and outside committees. The stock manipulators have no data. They attacked us at $1, $3, and on a regular basis on the way up the over $20. A landmark cancer study with clinical benefit in an unmet need cannot be held down.
  • D
    David
    $CVM conversation
    Geert Kersten
    @GeertKersten1
    ·
    May 17, 2021
    $CVM ‘s work is checked regularly by regulators and outside committees. The stock manipulators have no data. They attacked us at $1, $3, and on a regular basis on the way up the over $20. A landmark cancer study with clinical benefit in an unmet need cannot be held down.
  • D
    David
    $CVM conversation
    Final famous last words

    Adam Feuerstein
    @adamfeuerstein
    ·
    Sep 7, 2021
    The best Twitter today is the $CVM retail longs trying to convince the blown-up $SAVA retail longs that they should jump on board because Cel-Sci is legit, unlike Cassava.

    Great entertainment.
  • D
    David
    $CVM conversation
    Geert Kersten
    @GeertKersten1
    ·
    Feb 24, 2021
    $CVM The last FDA approval for advanced primary head & neck cancer was over 50 years ago. In the last 12 months both Pfizer and Astra Zeneca failed in H&N cancer. Unmet need. We just cannot see how our Phase 3 study will fail to show survival benefit. That is all that matters!